TNFRSF8 and neoplasm: In vivo, tumour accumulation results showed promising potency of the PET tracer, with 2.6%ID/g for [131I]-5F11 and 12.3%ID/g for [131I]Ki-4.305 Schnell et al. used [131I]Ki-4 to treat 22 patients with relapsed or refractory CD30-positive refractory Hodgkin’s lymphoma.